Since
2021
The Netherlands
Devices for treatment
TRL 8

Challenge

Approximately 20% of people suffer from chronic pain. Chronic pain reduces the quality of life for people affected by it. It also stops them from living their normal lives and reduces their ability to contribute to society.
Current treatment of pain consists primarily of medication: paracetamol, NSAIDs (e.g. ibuprofen, naproxen). Other therapies are physiotherapy, acupuncture or surgery. These treatments are medical, require a healthcare professional or are invasive.

Opportunity

Pain is a widespread problem, and the market for current solutions very large (50B+). There is a significant unmet consumer need for effective, safe pain relief options that can be applied at home by the patient themselves. 

Solution

We have agreed to build a venture with Philips that brings several solutions to market for effective, at-home Pain Relief. It offers patients pain relief through three propositions: PulseRelief, InfraRed and BlueTouch. All three options are non-invasive, perfectly safe for at-home use with no to limited guidance of a care professional.
Pulse Relief offers relief through transcutaneous electrical nerve stimulation (TENS) therapy. InfraRed consists of several products that offer relief through infrared light. BlueTouch offers a highly promising and new-to-the-world method for relief using blue light, with potentially break-through clinical benefits.

Status

InfraCare and PulseRelief are expected to launch in 2022 and 2023 respectively. BlueTouch’s innovative therapy is expected to demonstrate its effectiveness in a clinical trial starting in two years.

Meet the team

Pieter Wijffels (1)

Pieter Wijffels

Venture Partner

Pieter joined NLC in April 2020 as a Venture Partner. Before joining NLC, he spent 15 years at Philips, bringing innovation to life across the globe. He enjoys working in fast-paced environments and supporting initiatives that truly improve people’s lives.